<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="308462">
  <stage>Registered</stage>
  <submitdate>18/08/2010</submitdate>
  <approvaldate>24/08/2010</approvaldate>
  <actrnumber>ACTRN12610000697088</actrnumber>
  <trial_identification>
    <studytitle>Ciclosporine Azathioprine versus Tacrolimus mycophenolate mofetil in renal transplantation</studytitle>
    <scientifictitle>A randomized prospective open trial comparing cyclosporine/azathioprine versus tacrolimus/mycophenolate mofetil , associated to rabbit anti-thymocyte globulines (rATG) induction and prednisone in kidney transplantation</scientifictitle>
    <utrn>U1111-1116-6101</utrn>
    <trialacronym>CATM2</trialacronym>
    <secondaryid>CRG020600037 (Cochrane Renal Group - CRG)</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>renal transplantation</healthcondition>
    <healthcondition>Immunosuppressive treatment in renal transplantation</healthcondition>
    <healthcondition>Acute rejection and transplant survival in renal transplantation</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Tacrolimus 0.075 mg/Kg/twice daily oral tablet &amp; mycophenolate mofetil 1000 mg/twice daily oral tablet. The duration of the two treatments is prolonged during all the graft survival duration.</interventions>
    <comparator>Ciclosporine 6 mg/kgTwice daily, oral tablet &amp; azathioprine 3 mg/Kg/day, once daily, oral tablet. The duration of the two treatments is prolonged during all the graft survival duration.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Clinical acute rejection during the first year, assessed by an unexplained 20% increase of serum creatinine. All clinical rejections indicate a transplant biopsy.</outcome>
      <timepoint>1 year after the graft.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>patient survival assessed by the clinical confirmation that the patient is alive</outcome>
      <timepoint>1 year and 3 year after the graft</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>kidney survival assessed by the clinical confirmation that the patient is not treated by dyalisis and alive</outcome>
      <timepoint>1 year and 3 year after the graft</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>kidney function by evaluated Glomerular filtration rate (eGFR) evaluated by Modification of the Diet in Renal Disease simplified formula (MDRD) using creatinine blood level</outcome>
      <timepoint>1 year and 3 year after graft</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>diabetes assessed by glucose blood level and/or the need of diabetes treatment.</outcome>
      <timepoint>1 year and 3 year after the graft</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>patient with chronic renal failure indicating a renal transplantation</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>recipient hepatitis B surface antigen positive
older 65 years</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Educational / counselling / training</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>randomisation when the kidney graft is proposed to the patient, using a sealed opaque envelopes, without blind, after writed consent</concealment>
    <sequence>computer randomisation realized before the trial start.</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/02/2000</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>300</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>France</country>
      <state>bouches du rhone</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Assistance publique des Hopitaux de Marseille</primarysponsorname>
    <primarysponsoraddress>Centre de Nephrologie et Transplantation renale, Hopital de la Conception, AP-HM, 147 Bd Baille, 13005 Marseille, FRANCE</primarysponsoraddress>
    <primarysponsorcountry>France</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Assistance publique des Hopitaux de Marseille</fundingname>
      <fundingaddress>Centre de Nephrologie et Transplantation renale, Hopital de la Conception, AP-HM, 147 Bd Baille, 13005 Marseille, FRANCE</fundingaddress>
      <fundingcountry>France</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Randomized and open monocentral trial evaluating 2 immunosupressive regiments in prevention of acute rejection in renal transplantation.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Comite de Protection des Personnes Sud-Mediterranee II.</ethicname>
      <ethicaddress>CPP Sud-Mediterranee II - Hopital Salvator - 249 Boulevard Sainte Marguerite 13274 MARSEILLE cx 09</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>France</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr, Henri, Vacher-Coponat</name>
      <address>Medical Doctor, Service de Nephrologie, Hopital Conception, Assistance publique des Hopitaux de Marseille, 147 Bd Baille 13005 Marseille , France</address>
      <phone>+33 4 91 38 30 42</phone>
      <fax />
      <email>hvacher@mail.ap-hm.fr</email>
      <country>France</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr, Henri, Vacher-Coponat</name>
      <address>Medical Doctor, Service de Nephrologie, Hopital Conception, Assistance publique des Hopitaux de Marseille, 147 Bd Baille 13005 Marseille , France</address>
      <phone>+33 4 91 38 30 42</phone>
      <fax />
      <email>hvacher@mail.ap-hm.fr</email>
      <country>France</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr, Henri, Vacher-Coponat</name>
      <address>Medical Doctor, Service de Nephrologie, Hopital Conception, Assistance publique des H?pitaux de Marseille, 147 Bd Baille 13005 Marseille , France</address>
      <phone>+33 4 91 38 30 42</phone>
      <fax />
      <email>hvacher@mail.ap-hm.fr</email>
      <country>France</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>